The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Official Title: A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT04666129
Brief Summary: This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).
Detailed Description: This is a three-part, open-label, parallel-cohort study to assess the safety and tolerability of relugolix as the ADT component in combination treatment with abiraterone acetate plus a corticosteroid in patients with mCSPC or mCRPC (Part 1), apalutamide in patients with mCSPC or nmCRPC (Part 2), or docetaxel with or without prednisone in patients with mCSPC or mCRPC (Part 3). The study will consist of a 45-day screening period followed by a 12-week treatment period with one of the three combination treatments (Parts 1, 2, or 3). All participants are required to be currently or previously treated with a GnRH receptor antagonist (analog), leuprolide acetate or triptorelin, or a GnRH receptor antagonist, degarelix or relugolix, in combination with either abiraterone plus prednisone (Part 1), apalutamide (Part 2), or docetaxel (Part 3). The study consists of a 12-week primary study treatment period in which safety and tolerability, including assessment of vital sign measurements, ECGs, clinical laboratory tests and reporting of adverse events every 2 to 4 weeks, followed by a 40-week safety extension treatment period during which adverse events and changes to concomitant medications will be reported. The total treatment duration is 52 weeks.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
Arkansas Urology, Little Rock, Arkansas, United States
Colorodo Clinical Research, Lakewood, Colorado, United States
Chesapeake Urology Research Associates, Baltimore, Maryland, United States
University of Massachusetts Medical School, Worcester, Massachusetts, United States
New Jersey Urology, Saddle Brook, New Jersey, United States
Clinical Research Alliance, Inc., Westbury, New York, United States
Alliance Urology, Greensboro, North Carolina, United States
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
Helios Clinical Research, LLC., Middleburg Heights, Ohio, United States
Center for Advanced Urology, LLP d/b/a: MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States
Keystone Urology Specialists, Lancaster, Pennsylvania, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Urology Associates, P.C., Nashville, Tennessee, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Urology San Antonio, San Antonio, Texas, United States
Name: Mike Ufer
Affiliation: Sumitomo Pharma America, Inc.
Role: STUDY_DIRECTOR